{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:24:28Z","timestamp":1784823868874,"version":"3.55.0"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["25JRRA304"],"award-info":[{"award-number":["25JRRA304"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Laboratory of Gastrointestinal Tumor Diagnosis and Treatment of the National Health Commission","award":["NHCDP2022001"],"award-info":[{"award-number":["NHCDP2022001"]}]},{"name":"Gansu Provincial Hospital","award":["22GSSYA-3"],"award-info":[{"award-number":["22GSSYA-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08278-9","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:47:27Z","timestamp":1779277647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A review of organoid\u2013immune co-culture platforms to model the immune microenvironment of hepatocellular carcinoma and guide immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Wen-Wen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Shuai","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"8278_CR1","doi-asserted-by":"publisher","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","DOI":"10.1038\/s41572-020-00240-3"},{"key":"8278_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380:1450\u201362. https:\/\/doi.org\/10.1056\/NEJMra1713263.","journal-title":"N Engl J Med"},{"key":"8278_CR3","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.3390\/ijms23073778","volume":"23","author":"Z Sas","year":"2022","unstructured":"Sas Z, Cendrowicz E, Weinh\u00e4user I, Rygiel TP. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. Int J Mol Sci. 2022;23:3778. https:\/\/doi.org\/10.3390\/ijms23073778.","journal-title":"Int J Mol Sci"},{"key":"8278_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","volume":"19","author":"M Ringelhan","year":"2018","unstructured":"Ringelhan M, Pfister D, O\u2019Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222\u201332. https:\/\/doi.org\/10.1038\/s41590-018-0044-z.","journal-title":"Nat Immunol"},{"key":"8278_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151\u201372. https:\/\/doi.org\/10.1038\/s41571-021-00573-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"8278_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/hep.23054","volume":"50","author":"B Hoechst","year":"2009","unstructured":"Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 2009;50:799\u2013807. https:\/\/doi.org\/10.1002\/hep.23054.","journal-title":"Hepatology"},{"key":"8278_CR7","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.3390\/ijms16023307","volume":"16","author":"Y Kondo","year":"2015","unstructured":"Kondo Y, Shimosegawa T, Kondo Y, Shimosegawa T. Significant Roles of Regulatory T Cells and Myeloid Derived Suppressor Cells in Hepatitis B Virus Persistent Infection and Hepatitis B Virus-Related HCCs. Int J Mol Sci. 2015;16:3307\u201322. https:\/\/doi.org\/10.3390\/ijms16023307.","journal-title":"Int J Mol Sci"},{"key":"8278_CR8","doi-asserted-by":"publisher","first-page":"910","DOI":"10.5114\/aoms.2016.63743","volume":"14","author":"M Kapa\u0142czy\u0144ska","year":"2018","unstructured":"Kapa\u0142czy\u0144ska M, Kolenda T, Przyby\u0142a W, Zaj\u0105czkowska M, Teresiak A, Filas V, Ibbs M, Bli\u017aniak R, \u0141uczewski \u0141, Lamperska K. 2D and 3D cell cultures \u2013 a comparison of different types of cancer cell cultures. Arch Med Sci. 2018;14:910\u20139. https:\/\/doi.org\/10.5114\/aoms.2016.63743.","journal-title":"Arch Med Sci"},{"key":"8278_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41392-022-01024-9","volume":"7","author":"X-Y Tang","year":"2022","unstructured":"Tang X-Y, Wu S, Wang D, Chu C, Hong Y, Tao M, Hu H, Xu M, Guo X, Liu Y. Human organoids in basic research and clinical applications. Sig Transduct Target Ther. 2022;7:168. https:\/\/doi.org\/10.1038\/s41392-022-01024-9.","journal-title":"Sig Transduct Target Ther"},{"key":"8278_CR10","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1002\/mco2.274","volume":"4","author":"S Yang","year":"2023","unstructured":"Yang S, Hu H, Kung H, Zou R, Dai Y, Hu Y, Wang T, Lv T, Yu J, Li F. Organoids: The current status and biomedical applications. MedComm. 2023;4:e274. https:\/\/doi.org\/10.1002\/mco2.274.","journal-title":"MedComm"},{"key":"8278_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s43586-022-00174-y","volume":"2","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Chen X, Dowbaj AM, Sljukic A, Bratlie K, Lin L, Fong ELS, Balachander GM, Chen Z, Soragni A, et al. Organoids. Nat Rev Methods Primers. 2022;2:94. https:\/\/doi.org\/10.1038\/s43586-022-00174-y.","journal-title":"Nat Rev Methods Primers"},{"key":"8278_CR12","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4438","volume":"23","author":"L Broutier","year":"2017","unstructured":"Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarr\u00f3 LM, Bradshaw CR, Allen GE, Arnes-Benito R, Sidorova O, Gaspersz MP, et al. Human primary liver cancer\u2013derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23:1424\u201335. https:\/\/doi.org\/10.1038\/nm.4438.","journal-title":"Nat Med"},{"key":"8278_CR13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.celrep.2018.07.001","volume":"24","author":"S Nuciforo","year":"2018","unstructured":"Nuciforo S, Fofana I, Matter MS, Blumer T, Calabrese D, Boldanova T, Piscuoglio S, Wieland S, Ringnalda F, Schwank G, et al. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Cell Rep. 2018;24:1363\u201376. https:\/\/doi.org\/10.1016\/j.celrep.2018.07.001.","journal-title":"Cell Rep"},{"key":"8278_CR14","doi-asserted-by":"publisher","first-page":"e006290","DOI":"10.1136\/jitc-2022-006290","volume":"11","author":"L Magr\u00e9","year":"2023","unstructured":"Magr\u00e9 L, Verstegen MMA, Buschow S, van der Laan LJW, Peppelenbosch M, Desai J. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. J Immunother Cancer. 2023;11:e006290. https:\/\/doi.org\/10.1136\/jitc-2022-006290.","journal-title":"J Immunother Cancer"},{"key":"8278_CR15","doi-asserted-by":"publisher","first-page":"770465","DOI":"10.3389\/fimmu.2022.770465","volume":"13","author":"C-P Sun","year":"2022","unstructured":"Sun C-P, Lan H-R, Fang X-L, Yang X-Y, Jin K-T. Organoid Models for Precision Cancer Immunotherapy. Front Immunol. 2022;13:770465. https:\/\/doi.org\/10.3389\/fimmu.2022.770465.","journal-title":"Front Immunol"},{"key":"8278_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407\u201318. https:\/\/doi.org\/10.1038\/s41568-018-0007-6.","journal-title":"Nat Rev Cancer"},{"key":"8278_CR17","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","volume":"175","author":"JT Neal","year":"2018","unstructured":"Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou S-H, Salahudeen AA, Smith AR, et al. Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018;175:1972\u2013e198816. https:\/\/doi.org\/10.1016\/j.cell.2018.11.021.","journal-title":"Cell"},{"key":"8278_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature12271","volume":"499","author":"T Takebe","year":"2013","unstructured":"Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang R-R, Ueno Y, Zheng Y-W, Koike N, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013;499:481\u20134. https:\/\/doi.org\/10.1038\/nature12271.","journal-title":"Nature"},{"key":"8278_CR19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/ncb3312","volume":"18","author":"A Fatehullah","year":"2016","unstructured":"Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease. Nat Cell Biol. 2016;18:246\u201354. https:\/\/doi.org\/10.1038\/ncb3312.","journal-title":"Nat Cell Biol"},{"key":"8278_CR20","doi-asserted-by":"publisher","first-page":"1247125","DOI":"10.1126\/science.1247125","volume":"345","author":"MA Lancaster","year":"2014","unstructured":"Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345:1247125. https:\/\/doi.org\/10.1126\/science.1247125.","journal-title":"Science"},{"key":"8278_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2018;172:373\u2013e38610. https:\/\/doi.org\/10.1016\/j.cell.2017.11.010.","journal-title":"Cell"},{"key":"8278_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","volume":"159","author":"D Gao","year":"2014","unstructured":"Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159:176\u201387. https:\/\/doi.org\/10.1016\/j.cell.2014.08.016.","journal-title":"Cell"},{"key":"8278_CR23","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","volume":"174","author":"KK Dijkstra","year":"2018","unstructured":"Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, Van De Haar J, Fanchi LF, Slagter M, Van Der Velden DL, Kaing S, Kelderman S, et al. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell. 2018;174:1586\u2013e159812. https:\/\/doi.org\/10.1016\/j.cell.2018.07.009.","journal-title":"Cell"},{"key":"8278_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/path.4133","volume":"229","author":"A Mantovani","year":"2013","unstructured":"Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229:176\u201385. https:\/\/doi.org\/10.1002\/path.4133.","journal-title":"J Pathol"},{"key":"8278_CR25","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.3390\/cancers13122899","volume":"13","author":"K Arvanitakis","year":"2021","unstructured":"Arvanitakis K, Mitroulis I, Germanidis G. Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy. Cancers. 2021;13:2899. https:\/\/doi.org\/10.3390\/cancers13122899.","journal-title":"Cancers"},{"key":"8278_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","volume":"16","author":"ZG Fridlender","year":"2009","unstructured":"Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN. Cancer Cell. 2009;16:183\u201394. https:\/\/doi.org\/10.1016\/j.ccr.2009.06.017.","journal-title":"Cancer Cell"},{"key":"8278_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u201368. https:\/\/doi.org\/10.1038\/nri3175.","journal-title":"Nat Rev Immunol"},{"key":"8278_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/ni.1818","volume":"11","author":"K Wing","year":"2010","unstructured":"Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11:7\u201313. https:\/\/doi.org\/10.1038\/ni.1818.","journal-title":"Nat Immunol"},{"key":"8278_CR29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41419-024-06976-0","volume":"15","author":"L Co\u00ebnon","year":"2024","unstructured":"Co\u00ebnon L, Geindreau M, Ghiringhelli F, Villalba M, Bruchard M. Natural Killer cells at the frontline in the fight against cancer. Cell Death Dis. 2024;15:614. https:\/\/doi.org\/10.1038\/s41419-024-06976-0.","journal-title":"Cell Death Dis"},{"key":"8278_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399\u2013416. https:\/\/doi.org\/10.1038\/nrclinonc.2016.217.","journal-title":"Nat Rev Clin Oncol"},{"key":"8278_CR31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399. https:\/\/doi.org\/10.1038\/nri3862.","journal-title":"Nat Rev Immunol"},{"key":"8278_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7\u201324. https:\/\/doi.org\/10.1038\/s41577-019-0210-z.","journal-title":"Nat Rev Immunol"},{"key":"8278_CR33","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.3390\/cancers12123816","volume":"12","author":"L Holokai","year":"2020","unstructured":"Holokai L, Chakrabarti J, Lundy J, Croagh D, Adhikary P, Richards SS, Woodson C, Steele N, Kuester R, Scott A, et al. Murine- and Human-Derived Autologous Organoid\/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Cancers. 2020;12:3816. https:\/\/doi.org\/10.3390\/cancers12123816.","journal-title":"Cancers"},{"key":"8278_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62\u20138. https:\/\/doi.org\/10.1126\/science.aaa4967.","journal-title":"Science"},{"key":"8278_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.intimp.2014.08.002","volume":"23","author":"W Chanput","year":"2014","unstructured":"Chanput W, Mes JJ, Wichers HJ. THP-1 cell line: an in vitro cell model for immune modulation approach. Int Immunopharmacol. 2014;23:37\u201345. https:\/\/doi.org\/10.1016\/j.intimp.2014.08.002.","journal-title":"Int Immunopharmacol"},{"key":"8278_CR36","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, Sarin KY, Brown RA, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25:1251\u20139. https:\/\/doi.org\/10.1038\/s41591-019-0522-3.","journal-title":"Nat Med"},{"key":"8278_CR37","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","volume":"9","author":"T Duhen","year":"2018","unstructured":"Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9:2724. https:\/\/doi.org\/10.1038\/s41467-018-05072-0.","journal-title":"Nat Commun"},{"key":"8278_CR38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41577-019-0248-y","volume":"20","author":"YE Bar-Ephraim","year":"2020","unstructured":"Bar-Ephraim YE, Kretzschmar K, Clevers H. Organoids in immunological research. Nat Rev Immunol. 2020;20:279\u201393. https:\/\/doi.org\/10.1038\/s41577-019-0248-y.","journal-title":"Nat Rev Immunol"},{"key":"8278_CR39","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nrm2236","volume":"8","author":"F Pampaloni","year":"2007","unstructured":"Pampaloni F, Reynaud EG, Stelzer EHK. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8:839\u201345. https:\/\/doi.org\/10.1038\/nrm2236.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8278_CR40","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nbt.2989","volume":"32","author":"SN Bhatia","year":"2014","unstructured":"Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760\u201372. https:\/\/doi.org\/10.1038\/nbt.2989.","journal-title":"Nat Biotechnol"},{"key":"8278_CR41","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.stem.2018.02.011","volume":"22","author":"K Ronaldson-Bouchard","year":"2018","unstructured":"Ronaldson-Bouchard K, Vunjak-Novakovic G. Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development. Cell Stem Cell. 2018;22:310\u201324. https:\/\/doi.org\/10.1016\/j.stem.2018.02.011.","journal-title":"Cell Stem Cell"},{"key":"8278_CR42","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1039\/b901377f","volume":"9","author":"JH Sung","year":"2009","unstructured":"Sung JH, Shuler ML. A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip. 2009;9:1385\u201394. https:\/\/doi.org\/10.1039\/b901377f.","journal-title":"Lab Chip"},{"key":"8278_CR43","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.drudis.2016.07.003","volume":"21","author":"A Skardal","year":"2016","unstructured":"Skardal A, Shupe T, Atala A. Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. Drug Discov Today. 2016;21:1399\u2013411. https:\/\/doi.org\/10.1016\/j.drudis.2016.07.003.","journal-title":"Drug Discov Today"},{"key":"8278_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","volume":"42","author":"A Baessler","year":"2024","unstructured":"Baessler A, Vignali DAA. T Cell Exhaustion. Annu Rev Immunol. 2024;42:179\u2013206. https:\/\/doi.org\/10.1146\/annurev-immunol-090222-110914.","journal-title":"Annu Rev Immunol"},{"key":"8278_CR45","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1172\/JCI24480","volume":"115","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8\u2009+\u2009T cells. J Clin Invest. 2005;115:1616\u201326. https:\/\/doi.org\/10.1172\/JCI24480.","journal-title":"J Clin Invest"},{"key":"8278_CR46","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O\u2019Connor RS, Hwang W-T, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371. https:\/\/doi.org\/10.1038\/s41591-018-0010-1.","journal-title":"Nat Med"},{"key":"8278_CR47","doi-asserted-by":"publisher","first-page":"e0193498","DOI":"10.1371\/journal.pone.0193498","volume":"13","author":"F Cerignoli","year":"2018","unstructured":"Cerignoli F, Abassi YA, Lamarche BJ, Guenther G, Ana DS, Guimet D, Zhang W, Zhang J, Xi B. In vitro immunotherapy potency assays using real-time cell analysis. PLoS ONE. 2018;13:e0193498. https:\/\/doi.org\/10.1371\/journal.pone.0193498.","journal-title":"PLoS ONE"},{"key":"8278_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev-immunol-032414-112248","volume":"33","author":"FK-M Chan","year":"2015","unstructured":"Chan FK-M, Luz NF, Moriwaki K. Programmed necrosis in the cross talk of cell death and inflammation. Annu Rev Immunol. 2015;33:79\u2013106. https:\/\/doi.org\/10.1146\/annurev-immunol-032414-112248.","journal-title":"Annu Rev Immunol"},{"key":"8278_CR49","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486\u2013541. https:\/\/doi.org\/10.1038\/s41418-017-0012-4.","journal-title":"Cell Death Differ"},{"key":"8278_CR50","doi-asserted-by":"publisher","first-page":"e100928","DOI":"10.15252\/embj.2018100928","volume":"38","author":"TE Schnalzger","year":"2019","unstructured":"Schnalzger TE, de Groot MH, Zhang C, Mosa MH, Michels BE, R\u00f6der J, Darvishi T, Wels WS, Farin HF. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids. EMBO J. 2019;38:e100928. https:\/\/doi.org\/10.15252\/embj.2018100928.","journal-title":"EMBO J"},{"key":"8278_CR51","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Amant F, Biankin AV, Budinsk\u00e1 E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, M\u00e6landsmo GM, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998\u20131013. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0001.","journal-title":"Cancer Discov"},{"key":"8278_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","volume":"29","author":"K Kohli","year":"2022","unstructured":"Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29:10\u201321. https:\/\/doi.org\/10.1038\/s41417-021-00303-x.","journal-title":"Cancer Gene Ther"},{"key":"8278_CR53","doi-asserted-by":"publisher","first-page":"e13115","DOI":"10.1111\/cpr.13115","volume":"54","author":"M Xu","year":"2021","unstructured":"Xu M, Wang Y, Xia R, Wei Y, Wei X. Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting. Cell Prolif. 2021;54:e13115. https:\/\/doi.org\/10.1111\/cpr.13115.","journal-title":"Cell Prolif"},{"key":"8278_CR54","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s00262-021-02853-3","volume":"70","author":"S Goto","year":"2021","unstructured":"Goto S, Sakoda Y, Adachi K, Sekido Y, Yano S, Eto M, Tamada K. Enhanced anti-tumor efficacy of IL-7\/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. Cancer Immunol Immunother. 2021;70:2503\u201315. https:\/\/doi.org\/10.1007\/s00262-021-02853-3.","journal-title":"Cancer Immunol Immunother"},{"key":"8278_CR55","doi-asserted-by":"publisher","first-page":"958082","DOI":"10.3389\/fimmu.2022.958082","volume":"13","author":"F Li","year":"2022","unstructured":"Li F, Zhao S, Wei C, Hu Y, Xu T, Xin X, Zhu T, Shang L, Ke S, Zhou J, et al. Development of Nectin4\/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors. Front Immunol. 2022;13:958082. https:\/\/doi.org\/10.3389\/fimmu.2022.958082.","journal-title":"Front Immunol"},{"key":"8278_CR56","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004.","journal-title":"Cell Syst"},{"key":"8278_CR57","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, et al. Defining \u2018T cell exhaustion\u2019. Nat Rev Immunol. 2019;19:665\u201374. https:\/\/doi.org\/10.1038\/s41577-019-0221-9.","journal-title":"Nat Rev Immunol"},{"key":"8278_CR58","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews LP, Butler SC, Cui J, Cillo AR, Cardello C, Liu C, Brunazzi EA, Baessler A, Xie B, Kunning SR, et al. LAG-3 and PD-1 synergize on CD8\u2009+\u2009T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity. Cell. 2024;187:4355\u2013e437222. https:\/\/doi.org\/10.1016\/j.cell.2024.07.016.","journal-title":"Cell"},{"key":"8278_CR59","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","volume":"48","author":"LK Smith","year":"2018","unstructured":"Smith LK, Boukhaled GM, Condotta SA, Mazouz S, Guthmiller JJ, Vijay R, Butler NS, Bruneau J, Shoukry NH, Krawczyk CM, et al. INTERLEUKIN-10 DIRECTLY INHIBITS CD8\u2009+\u2009T CELL FUNCTION BY ENHANCING N-GLYCAN BRANCHING TO DECREASE ANTIGEN SENSITIVITY. Immunity. 2018;48:299\u2013e3125. https:\/\/doi.org\/10.1016\/j.immuni.2018.01.006.","journal-title":"Immunity"},{"key":"8278_CR60","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.3390\/cancers14051236","volume":"14","author":"R Li","year":"2022","unstructured":"Li R, Mukherjee MB, Lin J. Coordinated Regulation of Myeloid-Derived Suppressor Cells by Cytokines and Chemokines. Cancers. 2022;14:1236. https:\/\/doi.org\/10.3390\/cancers14051236.","journal-title":"Cancers"},{"key":"8278_CR61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276:121\u201344. https:\/\/doi.org\/10.1111\/imr.12528.","journal-title":"Immunol Rev"},{"key":"8278_CR62","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jhep.2020.10.021","volume":"74","author":"J Wang","year":"2021","unstructured":"Wang J, Wang Y, Chu Y, Li Z, Yu X, Huang Z, Xu J, Zheng L. Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma. J Hepatol. 2021;74:627\u201337. https:\/\/doi.org\/10.1016\/j.jhep.2020.10.021.","journal-title":"J Hepatol"},{"key":"8278_CR63","doi-asserted-by":"publisher","unstructured":"Zou Z, Lin Z, Wu C, Tan J, Zhang J, Peng Y, Zhang K, Li J, Wu M, Zhang Y. Micro-engineered organoid\u2010on\u2010a\u2010chip based on mesenchymal stromal cells to predict immunotherapy responses of HCC patients. Adv Sci. 2023;10. https:\/\/doi.org\/10.1002\/advs.202302640.","DOI":"10.1002\/advs.202302640"},{"key":"8278_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","volume":"66","author":"X Li","year":"2017","unstructured":"Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, et al. Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66:157\u201367. https:\/\/doi.org\/10.1136\/gutjnl-2015-310514.","journal-title":"Gut"},{"key":"8278_CR65","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41419-024-06888-z","volume":"15","author":"D Li","year":"2024","unstructured":"Li D, Zhang T, Guo Y, Bi C, Liu M, Wang G. Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma. Cell Death Dis. 2024;15:498. https:\/\/doi.org\/10.1038\/s41419-024-06888-z.","journal-title":"Cell Death Dis"},{"key":"8278_CR66","doi-asserted-by":"publisher","first-page":"121527","DOI":"10.1016\/j.biomaterials.2022.121527","volume":"284","author":"JTC Lim","year":"2022","unstructured":"Lim JTC, Kwang LG, Ho NCW, Toh CCM, Too NSH, Hooi L, Benoukraf T, Chow PK-H, Dan YY, Chow EK-H, et al. Hepatocellular carcinoma organoid co-cultures mimic angiocrine crosstalk to generate inflammatory tumor microenvironment. Biomaterials. 2022;284:121527. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121527.","journal-title":"Biomaterials"},{"key":"8278_CR67","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1007\/s12672-025-03138-2","volume":"16","author":"S Tavakoli","year":"2025","unstructured":"Tavakoli S, Samareh-Salavati M, Rahnama MA, Abdolahi S, Hassanzadeh A, Ghazvinian Z, Verdi J, Vousooghi N, Manoochehrabadi S, Chahardouli B, et al. Natural killer cell therapy in hepatocellular carcinoma: a comprehensive review. Discov Onc. 2025;16:1348. https:\/\/doi.org\/10.1007\/s12672-025-03138-2.","journal-title":"Discov Onc"},{"key":"8278_CR68","doi-asserted-by":"publisher","first-page":"118","DOI":"10.14336\/AD.2019.1017","volume":"11","author":"Q Luo","year":"2020","unstructured":"Luo Q, Luo W, Zhu Q, Huang H, Peng H, Liu R, Xie M, Li S, Li M, Hu X, et al. Tumor-Derived Soluble MICA Obstructs the NKG2D Pathway to Restrain NK Cytotoxicity. Aging Dis. 2020;11:118\u201328. https:\/\/doi.org\/10.14336\/AD.2019.1017.","journal-title":"Aging Dis"},{"key":"8278_CR69","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen S, Zhu H, Jounaidi Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Sig Transduct Target Ther. 2024;9:302. https:\/\/doi.org\/10.1038\/s41392-024-02005-w.","journal-title":"Sig Transduct Target Ther"},{"key":"8278_CR70","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","volume":"14","author":"N Pang","year":"2021","unstructured":"Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, Huang Y, Wu Q, Li X, He B, et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021;14:118. https:\/\/doi.org\/10.1186\/s13045-021-01128-9.","journal-title":"J Hematol Oncol"},{"key":"8278_CR71","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36:346\u201351. https:\/\/doi.org\/10.1038\/nbt.4086.","journal-title":"Nat Biotechnol"},{"key":"8278_CR72","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","volume":"20","author":"RD Leone","year":"2020","unstructured":"Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20:516\u201331. https:\/\/doi.org\/10.1038\/s41568-020-0273-y.","journal-title":"Nat Rev Cancer"},{"key":"8278_CR73","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/cdd.2017.3","volume":"24","author":"V Chiusolo","year":"2017","unstructured":"Chiusolo V, Jacquemin G, Yonca Bassoy E, Vinet L, Liguori L, Walch M, Kozjak-Pavlovic V, Martinvalet D. Granzyme B enters the mitochondria in a Sam50-, Tim22- and mtHsp70-dependent manner to induce apoptosis. Cell Death Differ. 2017;24:747\u201358. https:\/\/doi.org\/10.1038\/cdd.2017.3.","journal-title":"Cell Death Differ"},{"key":"8278_CR74","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.7150\/thno.101107","volume":"14","author":"Q Lin","year":"2024","unstructured":"Lin Q, Olkowski CP, Choyke PL, Sato N. Tumor growth suppression in adoptive T cell therapy via IFN-\u03b3 targeting of tumor vascular endothelial cells. Theranostics. 2024;14:6897\u2013912. https:\/\/doi.org\/10.7150\/thno.101107.","journal-title":"Theranostics"},{"key":"8278_CR75","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52:1475\u201385. https:\/\/doi.org\/10.1038\/s12276-020-00500-y.","journal-title":"Exp Mol Med"},{"key":"8278_CR76","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jcyt.2019.03.003","volume":"21","author":"T Gargett","year":"2019","unstructured":"Gargett T, Truong N, Ebert LM, Yu W, Brown MP. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. Cytotherapy. 2019;21:593\u2013602. https:\/\/doi.org\/10.1016\/j.jcyt.2019.03.003.","journal-title":"Cytotherapy"},{"key":"8278_CR77","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity. 2024;57:206\u201322. https:\/\/doi.org\/10.1016\/j.immuni.2024.01.010.","journal-title":"Immunity"},{"key":"8278_CR78","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7:737. https:\/\/doi.org\/10.1038\/s41598-017-00462-8.","journal-title":"Sci Rep"},{"key":"8278_CR79","doi-asserted-by":"publisher","unstructured":"Huang T, Ren X, Tang X, Wang Y, Ji R, Guo Q, Ma Q, Zheng Y, Hu Z, Zhou Y. Current perspectives and trends of CD39-CD73-eAdo\/A2aR research in tumor microenvironment: a bibliometric analysis. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1427380.","DOI":"10.3389\/fimmu.2024.1427380"},{"key":"8278_CR80","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2217\/imt.15.106","volume":"8","author":"D Allard","year":"2016","unstructured":"Allard D, Allard B, Gaudreau P-O, Chrobak P, Stagg J. CD73-adenosine: a next-generation target in immuno-oncology. Immunotherapy. 2016;8:145\u201363. https:\/\/doi.org\/10.2217\/imt.15.106.","journal-title":"Immunotherapy"},{"key":"8278_CR81","doi-asserted-by":"publisher","unstructured":"Goldmann O, Nwofor OV, Chen Q, Medina E. Mechanisms underlying immunosuppression by regulatory cells. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1328193.","DOI":"10.3389\/fimmu.2024.1328193"},{"key":"8278_CR82","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jss.2019.02.038","volume":"240","author":"D Imai","year":"2019","unstructured":"Imai D, Yoshizumi T, Okano S, Itoh S, Ikegami T, Harada N, Aishima S, Oda Y, Maehara Y. IFN-\u03b3 Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer. J Surg Res. 2019;240:115\u201323. https:\/\/doi.org\/10.1016\/j.jss.2019.02.038.","journal-title":"J Surg Res"},{"key":"8278_CR83","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.7150\/ijbs.82317","volume":"19","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li J, Lei W, Wang H, Ni Y, Liu Y, Yan H, Tian Y, Wang Z, Yang Z, et al. CXCL12-CXCR4\/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications. Int J Biol Sci. 2023;19:3341\u201359. https:\/\/doi.org\/10.7150\/ijbs.82317.","journal-title":"Int J Biol Sci"},{"key":"8278_CR84","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","volume":"105","author":"I Prager","year":"2019","unstructured":"Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019;105:1319\u201329. https:\/\/doi.org\/10.1002\/JLB.MR0718-269R.","journal-title":"J Leukoc Biol"},{"key":"8278_CR85","doi-asserted-by":"publisher","unstructured":"Russell L, Peng KW, Russell SJ, Diaz RM. Oncolytic Viruses: Priming Time for Cancer Immunotherapy. BioDrugs. 2019;33:485\u2013501. https:\/\/doi.org\/10.1007\/s40259-019-00367-0","DOI":"10.1007\/s40259-019-00367-0"},{"key":"8278_CR86","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","volume":"22","author":"C Xia","year":"2023","unstructured":"Xia C, Yin S, To KKW, Fu L. CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol Cancer. 2023;22:44. https:\/\/doi.org\/10.1186\/s12943-023-01733-x.","journal-title":"Mol Cancer"},{"key":"8278_CR87","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79:506\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.003.","journal-title":"J Hepatol"},{"key":"8278_CR88","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1126\/science.aaw6985","volume":"364","author":"D Tuveson","year":"2019","unstructured":"Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science. 2019;364:952\u20135. https:\/\/doi.org\/10.1126\/science.aaw6985.","journal-title":"Science"},{"key":"8278_CR89","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717\u201334. https:\/\/doi.org\/10.1038\/nrclinonc.2017.101.","journal-title":"Nat Rev Clin Oncol"},{"key":"8278_CR90","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fern\u00e1ndez-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920\u20136. https:\/\/doi.org\/10.1126\/science.aao2774.","journal-title":"Science"},{"key":"8278_CR91","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.ymthe.2021.01.021","volume":"29","author":"F Zou","year":"2021","unstructured":"Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, Li J. The CD39\u2009+\u2009HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8\u2009+\u2009T cells exhibit potent anti-HCC activity. Mol Ther. 2021;29:1794\u2013807. https:\/\/doi.org\/10.1016\/j.ymthe.2021.01.021.","journal-title":"Mol Ther"},{"key":"8278_CR92","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H, Astarita JL, Cubas R, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"key":"8278_CR93","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00262-022-03314-1","volume":"72","author":"AW Silk","year":"2022","unstructured":"Silk AW, O\u2019Day SJ, Kaufman HL, Bryan J, Norrell JT, Imbergamo C, Portal D, Zambrano-Acosta E, Palmeri M, Fein S, et al. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study. Cancer Immunol Immunother. 2022;72:1405\u201315. https:\/\/doi.org\/10.1007\/s00262-022-03314-1.","journal-title":"Cancer Immunol Immunother"},{"key":"8278_CR94","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.omto.2023.03.002","volume":"29","author":"M Holmes","year":"2023","unstructured":"Holmes M, Scott GB, Heaton S, Barr T, Askar B, M\u00fcller LME, Jennings VA, Ralph C, Burton C, Melcher A, et al. Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells. Mol Therapy - Oncolytics. 2023;29:17\u201329. https:\/\/doi.org\/10.1016\/j.omto.2023.03.002.","journal-title":"Mol Therapy - Oncolytics"},{"key":"8278_CR95","doi-asserted-by":"publisher","unstructured":"Aquino-L\u00f3pez A, Senyukov VV, Vlasic Z, Kleinerman ES, Lee DA. Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines. Front Immunol. 2017;8. https:\/\/doi.org\/10.3389\/fimmu.2017.00391.","DOI":"10.3389\/fimmu.2017.00391"},{"key":"8278_CR96","doi-asserted-by":"publisher","first-page":"1038226","DOI":"10.3389\/fimmu.2022.1038226","volume":"13","author":"L Palanivelu","year":"2023","unstructured":"Palanivelu L, Liu C-H, Lin L-T. Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. Front Immunol. 2023;13:1038226. https:\/\/doi.org\/10.3389\/fimmu.2022.1038226.","journal-title":"Front Immunol"},{"key":"8278_CR97","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130\u201344. https:\/\/doi.org\/10.1172\/JCI83092.","journal-title":"J Clin Invest"},{"key":"8278_CR98","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.it.2020.06.010","volume":"41","author":"K Yuki","year":"2020","unstructured":"Yuki K, Cheng N, Nakano M, Kuo CJ. Organoid Models of Tumor Immunology. Trends Immunol. 2020;41:652\u201364. https:\/\/doi.org\/10.1016\/j.it.2020.06.010.","journal-title":"Trends Immunol"},{"key":"8278_CR99","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/2159-8290.CD-17-0833","volume":"8","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018;8:196\u2013215. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0833.","journal-title":"Cancer Discov"},{"key":"8278_CR100","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/0008-5472.CAN-20-4026","volume":"81","author":"M Gr\u00f6nholm","year":"2021","unstructured":"Gr\u00f6nholm M, Feodoroff M, Antignani G, Martins B, Hamdan F, Cerullo V. Patient-Derived Organoids for Precision Cancer Immunotherapy. Cancer Res. 2021;81:3149\u201355. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-4026.","journal-title":"Cancer Res"},{"key":"8278_CR101","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","volume":"25","author":"NE Annels","year":"2019","unstructured":"Annels NE, Mansfield D, Arif M, Ballesteros-Merino C, Simpson GR, Denyer M, Sandhu SS, Melcher AA, Harrington KJ, Davies B, et al. Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2019;25:5818\u201331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4022.","journal-title":"Clin Cancer Res"},{"key":"8278_CR102","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1039\/D0LC01305F","volume":"21","author":"K Paterson","year":"2021","unstructured":"Paterson K, Zanivan S, Glasspool R, Coffelt B, Zagnoni S. Microfluidic technologies for immunotherapy studies on solid tumours. Lab Chip. 2021;21:2306\u201329. https:\/\/doi.org\/10.1039\/D0LC01305F.","journal-title":"Lab Chip"},{"key":"8278_CR103","doi-asserted-by":"publisher","unstructured":"Chambers AM, Matosevic S. Immunometabolic Dysfunction of Natural Killer Cells Mediated by the Hypoxia-CD73 Axis in Solid Tumors. Front Mol Biosci. 2019;6. https:\/\/doi.org\/10.3389\/fmolb.2019.00060.","DOI":"10.3389\/fmolb.2019.00060"},{"key":"8278_CR104","doi-asserted-by":"publisher","unstructured":"Barrett RL, Pur\u00e9 E. Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. eLife (2020) 9:e57243. https:\/\/doi.org\/10.7554\/eLife.57243","DOI":"10.7554\/eLife.57243"},{"key":"8278_CR105","doi-asserted-by":"publisher","first-page":"1602452","DOI":"10.3389\/fonc.2025.1602452","volume":"15","author":"W Hou","year":"2025","unstructured":"Hou W. Role of TGF\u03b2-activated cancer-associated fibroblasts in the resistance to checkpoint blockade immunotherapy. Front Oncol. 2025;15:1602452. https:\/\/doi.org\/10.3389\/fonc.2025.1602452.","journal-title":"Front Oncol"},{"key":"8278_CR106","doi-asserted-by":"publisher","first-page":"1367875","DOI":"10.3389\/fimmu.2024.1367875","volume":"15","author":"P Leone","year":"2024","unstructured":"Leone P, Malerba E, Susca N, Favoino E, Perosa F, Brunori G, Prete M, Racanelli V. Endothelial cells in tumor microenvironment: insights and perspectives. Front Immunol. 2024;15:1367875. https:\/\/doi.org\/10.3389\/fimmu.2024.1367875.","journal-title":"Front Immunol"},{"key":"8278_CR107","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.ccell.2024.09.001","volume":"42","author":"D Gong","year":"2024","unstructured":"Gong D, Arbesfeld-Qiu JM, Perrault E, Bae JW, Hwang WL. Spatial Oncology: Translating Contextual Biology to the Clinic. Cancer Cell. 2024;42:1653\u201375. https:\/\/doi.org\/10.1016\/j.ccell.2024.09.001.","journal-title":"Cancer Cell"},{"key":"8278_CR108","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41698-024-00752-1","volume":"8","author":"J Ye","year":"2024","unstructured":"Ye J, Lin Y, Liao Z, Gao X, Lu C, Lu L, Huang J, Huang X, Huang S, Yu H, et al. Single cell-spatial transcriptomics and bulk multi-omics analysis of heterogeneity and ecosystems in hepatocellular carcinoma. NPJ Precis Oncol. 2024;8:262. https:\/\/doi.org\/10.1038\/s41698-024-00752-1.","journal-title":"NPJ Precis Oncol"},{"key":"8278_CR109","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.21037\/jtd.2018.03.60","volume":"10","author":"CE McCoach","year":"2018","unstructured":"McCoach CE, Bivona TG. The evolving understanding of immunoediting and the clinical impact of immune escape. J Thorac Dis. 2018;10:1248\u201352. https:\/\/doi.org\/10.21037\/jtd.2018.03.60.","journal-title":"J Thorac Dis"},{"key":"8278_CR110","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021;12:636568. https:\/\/doi.org\/10.3389\/fimmu.2021.636568.","journal-title":"Front Immunol"},{"key":"8278_CR111","doi-asserted-by":"publisher","unstructured":"Zhang C, Wang K, Wang H. Adenosine in cancer immunotherapy: Taking off on a new plane. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) 1878:189005. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189005","DOI":"10.1016\/j.bbcan.2023.189005"},{"key":"8278_CR112","doi-asserted-by":"publisher","first-page":"e100300","DOI":"10.15252\/embj.2018100300","volume":"38","author":"N Sachs","year":"2019","unstructured":"Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, B\u00f6ttinger L, Klay D, Weeber F, Huelsz-Prince G, Iakobachvili N, Amatngalim GD, et al. Long-term expanding human airway organoids for disease modeling. EMBO J. 2019;38:e100300. https:\/\/doi.org\/10.15252\/embj.2018100300.","journal-title":"EMBO J"},{"key":"8278_CR113","doi-asserted-by":"publisher","unstructured":"Chi X, Luo S, Ye P, Hwang W-L, Cha J-H, Yan X, Yang W-H. T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1104771.","DOI":"10.3389\/fimmu.2023.1104771"},{"key":"8278_CR114","doi-asserted-by":"publisher","unstructured":"Gennert DG, Lynn RC, Granja JM, Weber EW, Mumbach MR, Zhao Y, Duren Z, Sotillo E, Greenleaf WJ, Wong WH et al. Dynamic chromatin regulatory landscape of human CAR T cell exhaustion. Proceedings of the National Academy of Sciences (2021) 118:e2104758118. https:\/\/doi.org\/10.1073\/pnas.2104758118","DOI":"10.1073\/pnas.2104758118"},{"key":"8278_CR115","doi-asserted-by":"publisher","first-page":"14375","DOI":"10.1002\/cam4.5943","volume":"12","author":"C Zhou","year":"2023","unstructured":"Zhou C, Wu Y, Wang Z, Liu Y, Yu J, Wang W, Chen S, Wu W, Wang J, Qian G, et al. Standardization of organoid culture in cancer research. Cancer Med. 2023;12:14375\u201386. https:\/\/doi.org\/10.1002\/cam4.5943.","journal-title":"Cancer Med"},{"key":"8278_CR116","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/jpm15080394","volume":"15","author":"FJ Di Paola","year":"2025","unstructured":"Di Paola FJ, Calafato G, Piccaluga PP, Tallini G, Rhoden KJ. Patient-Derived Organoid Biobanks for Translational Research and Precision Medicine: Challenges and Future Perspectives. J Pers Med. 2025;15:394. https:\/\/doi.org\/10.3390\/jpm15080394.","journal-title":"J Pers Med"},{"key":"8278_CR117","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1097\/CM9.0000000000003414","volume":"137","author":"R Yang","year":"2024","unstructured":"Yang R, Qi Y, Zhang X, Gao H, Yu Y. Living biobank: Standardization of organoid construction and challenges. Chin Med J. 2024;137:3050\u201360. https:\/\/doi.org\/10.1097\/CM9.0000000000003414.","journal-title":"Chin Med J"},{"key":"8278_CR118","doi-asserted-by":"publisher","first-page":"102619","DOI":"10.1016\/j.tranon.2025.102619","volume":"63","author":"Z Mi","year":"2025","unstructured":"Mi Z, Guan H, Zhang G, Li D, Yu Y, Qu J. From benchside avatars to bedside breakthroughs: Patient-derived organoids in the new era of cancer immunotherapy. Transl Oncol. 2025;63:102619. https:\/\/doi.org\/10.1016\/j.tranon.2025.102619.","journal-title":"Transl Oncol"},{"key":"8278_CR119","doi-asserted-by":"publisher","unstructured":"Zhao J, Fong A, Seow SV, Toh HC, Zhao J, Fong A, Seow SV, Toh HC. Organoids as an Enabler of Precision Immuno-Oncology. Cells. 2023;12. https:\/\/doi.org\/10.3390\/cells12081165.","DOI":"10.3390\/cells12081165"},{"key":"8278_CR120","doi-asserted-by":"publisher","first-page":"100606","DOI":"10.1016\/j.cobme.2025.100606","volume":"35","author":"V Bonnet","year":"2025","unstructured":"Bonnet V, Angelidakis E, Sart S, Baroud CN. Microfluidic and organ-on-a-chip approaches to model the tumor microenvironment. Curr Opin Biomedical Eng. 2025;35:100606. https:\/\/doi.org\/10.1016\/j.cobme.2025.100606.","journal-title":"Curr Opin Biomedical Eng"},{"key":"8278_CR121","doi-asserted-by":"publisher","unstructured":"Coppola C, Hopkins B, Huhn S, Du Z, Huang Z, Kelly WJ, Coppola C, Hopkins B, Huhn S, Du Z, et al. Investigation of the Impact from IL-2, IL-7, and IL-15 on the Growth and Signaling of Activated CD4\u2009+\u2009T Cells. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21217814.","DOI":"10.3390\/ijms21217814"},{"key":"8278_CR122","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1038\/s41388-024-03183-1","volume":"43","author":"R Antoon","year":"2024","unstructured":"Antoon R, Overdevest N, Saleh AH, Keating A. Mesenchymal stromal cells as cancer promoters. Oncogene. 2024;43:3545\u201355. https:\/\/doi.org\/10.1038\/s41388-024-03183-1.","journal-title":"Oncogene"},{"key":"8278_CR123","doi-asserted-by":"publisher","first-page":"150339","DOI":"10.1016\/j.bbrc.2024.150339","volume":"730","author":"Y Dong","year":"2024","unstructured":"Dong Y, Zhou X, Ding Y, Luo Y, Zhao H. Advances in tumor microenvironment: Applications and challenges of 3D bioprinting. Biochem Biophys Res Commun. 2024;730:150339. https:\/\/doi.org\/10.1016\/j.bbrc.2024.150339.","journal-title":"Biochem Biophys Res Commun"},{"key":"8278_CR124","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.drudis.2020.06.001","volume":"25","author":"S Lin","year":"2020","unstructured":"Lin S, Schorpp K, Rothenaigner I, Hadian K. Image-based high-content screening in drug discovery. Drug Discovery Today. 2020;25:1348\u201361. https:\/\/doi.org\/10.1016\/j.drudis.2020.06.001.","journal-title":"Drug Discovery Today"},{"key":"8278_CR125","doi-asserted-by":"publisher","unstructured":"Fei K, Zhang J, Yuan J, Xiao P, Fei K, Zhang J, Yuan J, Xiao P. Present Application and Perspectives of Organoid Imaging Technology. Bioengineering. 2022;9. https:\/\/doi.org\/10.3390\/bioengineering9030121.","DOI":"10.3390\/bioengineering9030121"},{"key":"8278_CR126","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971.","journal-title":"Science"},{"key":"8278_CR127","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017;171:1259\u2013e127111. https:\/\/doi.org\/10.1016\/j.cell.2017.10.001.","journal-title":"Cell"},{"key":"8278_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-91311-3_1","volume":"113","author":"JR Wilczy\u0144ski","year":"2022","unstructured":"Wilczy\u0144ski JR, Nowak M. Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors. Exp Suppl. 2022;113:1\u201357. https:\/\/doi.org\/10.1007\/978-3-030-91311-3_1.","journal-title":"Exp Suppl"},{"key":"8278_CR129","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43586-022-00118-6","volume":"2","author":"CM Leung","year":"2022","unstructured":"Leung CM, de Haan P, Ronaldson-Bouchard K, Kim G-A, Ko J, Rho HS, Chen Z, Habibovic P, Jeon NL, Takayama S, et al. A guide to the organ-on-a-chip. Nat Rev Methods Primers. 2022;2:33. https:\/\/doi.org\/10.1038\/s43586-022-00118-6.","journal-title":"Nat Rev Methods Primers"},{"key":"8278_CR130","doi-asserted-by":"publisher","first-page":"2314171","DOI":"10.1002\/adfm.202314171","volume":"34","author":"D Wu","year":"2024","unstructured":"Wu D, Pang S, Berg J, Mei Y, Ali ASM, R\u00f6hrs V, Tolksdorf B, Hagenbuchner J, Ausserlechner MJ, Deubzer HE, et al. Bioprinting of Perfusable Vascularized Organ Models for Drug Development via Sacrificial-Free Direct Ink Writing. Adv Funct Mater. 2024;34:2314171. https:\/\/doi.org\/10.1002\/adfm.202314171.","journal-title":"Adv Funct Mater"},{"key":"8278_CR131","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12929-022-00879-y","volume":"29","author":"W-C Hsieh","year":"2022","unstructured":"Hsieh W-C, Budiarto BR, Wang Y-F, Lin C-Y, Gwo M-C, So DK, Tzeng Y-S, Chen S-Y. Spatial multi-omics analyses of the tumor immune microenvironment. J Biomed Sci. 2022;29:96. https:\/\/doi.org\/10.1186\/s12929-022-00879-y.","journal-title":"J Biomed Sci"},{"key":"8278_CR132","doi-asserted-by":"publisher","first-page":"100909","DOI":"10.1016\/j.crmeth.2024.100909","volume":"4","author":"BP Sharpe","year":"2024","unstructured":"Sharpe BP, Nazlamova LA, Tse C, Johnston DA, Thomas J, Blyth R, Pickering OJ, Grace B, Harrington J, Rajak R, et al. Patient-derived tumor organoid and fibroblast assembloid models for interrogation of the tumor microenvironment in esophageal adenocarcinoma. Cell Rep Methods. 2024;4:100909. https:\/\/doi.org\/10.1016\/j.crmeth.2024.100909.","journal-title":"Cell Rep Methods"},{"key":"8278_CR133","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1007\/s10565-023-09821-w","volume":"39","author":"L-L Lu","year":"2023","unstructured":"Lu L-L, Xiao S, Lin Z, Bai J, Li W, Song Z, Zhou Y, Lu B, Wu W-Z. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy. Cell Biol Toxicol. 2023;39:3101\u201319. https:\/\/doi.org\/10.1007\/s10565-023-09821-w.","journal-title":"Cell Biol Toxicol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08278-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:09:14Z","timestamp":1784070554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08278-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":133,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8278"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08278-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"906"}}